Cilazapril
Names | |
---|---|
Preferred IUPAC name
(1S,9S)-9-{[(2S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-10-oxooctahydro-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid | |
Identifiers | |
3D model (
JSmol ) |
|
ChEBI | |
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard
|
100.168.764 |
IUPHAR/BPS |
|
KEGG | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C22H31N3O5 | |
Molar mass | 417.506 g·mol−1 |
log P | 2.212 |
Acidity (pKa) | 2.285 |
Basicity (pKb) | 11.712 |
Pharmacology | |
C09AA08 (WHO) | |
Oral | |
Legal status |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Cilazapril is an
It was patented in 1982 and approved for medical use in 1990.[3]
Chemistry
Of the eight possible
stereoisomers, only the all-(S)-form is medically viable.[citation needed
]
Brand names
It is branded as Dynorm, Inhibace, Vascace and many other names in various countries. None of these are available in the United States as of May 2010.[4]
References
- S2CID 261123720.
- ISBN 978-3-85200-181-4.
- ISBN 9783527607495.
- ^ "Cilazapril". Drugs.com. Retrieved 28 May 2010.